WASHINGTON — The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by Novo Nordisk and Eli Lilly — offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board.
The administration argued that giving millions more people access to these drugs represents a major victory in the fight against chronic disease. The precise timeline for the coverage expansion and the extent of who will gain access remain unclear.
Medicare and Medicaid will receive substantial discounts on the drugs, and will cover them for some individuals with overweight or obesity. The companies have agreed to sell the treatments for $245 a month across both programs for weight loss and diabetes. Medicare beneficiaries will have a $50 copay, and commercial plans will also receive discounts.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
